1
|
Overmoyer B, Regan M, Hu J, Nakhlis F, Dominici L, Lin NU, Freedman R, Morganstern DE, Partridge AH, Schlosnagle EJ, Hirshfield-Bartek J, Bellon J, Morikawa A, Harrison BT, Winer E. Abstract P6-15-11: Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-15-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inflammatory breast cancer (IBC) is inoperable at presentation, thus neoadjuvant systemic therapy (NAS) is the primary treatment for this aggressive disease. Due to its rarity, patients (pts) with IBC are incorporated into NAS clinical trials for locally advanced breast cancer, making it difficult to extrapolate efficacy specifically for pts with IBC. A commonly used regimen for the treatment of HER2+ IBC includes docetaxel, carboplatin, pertuzumab (P) and trastuzumab (H), yet only 6% of pts enrolled in the clinical trial for this regimen had IBC. We sought to examine the efficacy of maximizing anti-HER2 therapy combined with minimal chemotherapy using the THP regimen specifically for pts with HER2+ IBC.
Methods: Pts with newly diagnosed HER2+ IBC received NAS with 16 weeks (wks) of paclitaxel (T) 80mg/m2/wk, H (2mg/kg/wk) and P(420mg/kg/3wk) followed by modified radical mastectomy (MRM) on a phase II prospective study. All pts had 2 research breast biopsies (rbx) for correlative assays prior to and 1 wk after the P (840mg/kg) and H (4 mg/kg) loading dose. Pts who achieved a pCR (pathologic complete response) could opt out of adjuvant doxorubicin (A) 60 mg/m2 + cyclophosphamide (C) 600mg/m2 x 4; pts with residual disease received AC. All pts received post-mastectomy radiation and maintenance P (420mg) + H (6mg/kg) every 3 wks x 12. Adjuvant endocrine therapy was given per standard of care. Primary objective was pCR rate in the breast and axillary lymph nodes. Residual Cancer Burden (RCB) was assessed. Based upon a Simon two-stage design, this regimen would be declared worthy of further study if >7/27 pCR were observed (15% vs 40%; target α=0.039 power=0.90). The study was closed after 23/27 pts were enrolled due to slow accrual.
Results: 20 pts were enrolled as of 12/2016, 18 completed NAS and MRM. All but 1 had stage III disease at presentation. 1 pt was lost to follow-up; 1 developed CNS metastasis during NAS and did not undergo MRM. The mean age was 49 years, 10 pts had ER/PR negative disease. 15 pts completed 16 wks of T, 4 had 15 wks and 1 had 13 wks. During NAS, there was no grade (gd) 4 toxicity; 6 episodes of gd 3 toxicity (2 related to treatment-diarrhea); and no gd 3 cardiac events. In the intent to treat analysis, 10/20 pts achieved pCR (50%; 90% CI 30-70%) and 6 had RCB-1 (30%). 5 pts with RCB-1 response had <5 mm residual disease; 1 had lymph node involvement. Of those proceeding to MRM, pCR rate was 56% (10/18). 6/10 opted out of AC. Treatment and follow-up for clinical outcomes continue. Biologic correlatives investigating genomic profiling and patterns of HER2 resistance are being performed on rbx, residual disease and cfDNA.
Conclusion: THP x 16wks is tolerable and effective NAS for HER2+ IBC, resulting in a high pCR rate with minimal toxicity. This study of NAS explored the benefit of maximizing HER2-directed therapy and minimizing chemotherapy and its associated toxicity. It has achieved its primary endpoint and will be used as the backbone NAS for HER2+ IBC, with future studies building upon this regimen. The result of this trial supports the benefit of clinical trials designed specifically for pts with IBC. Clinical trial information: NCT01796197.
Citation Format: Overmoyer B, Regan M, Hu J, Nakhlis F, Dominici L, Lin NU, Freedman R, Morganstern DE, Partridge AH, Schlosnagle EJ, Hirshfield-Bartek J, Bellon J, Morikawa A, Harrison BT, Winer E. Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-15-11.
Collapse
Affiliation(s)
- B Overmoyer
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - M Regan
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - J Hu
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - F Nakhlis
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - L Dominici
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - NU Lin
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - R Freedman
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - DE Morganstern
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - AH Partridge
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - EJ Schlosnagle
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - J Hirshfield-Bartek
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - J Bellon
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - A Morikawa
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - BT Harrison
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| | - E Winer
- Dana Farber Cancer Institute, Boston, MA; Brigham and Womens Hospital, Boston, MA; University of Michigan, Ann Arbor, MI
| |
Collapse
|
2
|
Overmoyer B, Goel S, Regan M, Hirshfield-Bartek J, Schlosnagel E, Yeh E, Qin L, Bellon J, Nakhlis F, Jacene H, Winer E. Abstract OT1-01-07: A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot1-01-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2 negative(neg) inflammatory breast cancer(IBC) exhibits relative resistance to chemotherapy evidenced by pCR(pathologic complete response rate) rates of 12-25% with preoperative taxane/anthracycline regimens. Eribulin(Eisai®) inhibits microtubular function via sequestration of tubulin into nonfunctional aggregates, thus being effective against taxane-resistant cancer. Preclinical data shows 2 mechanisms of action: reversion of EMT(epithelial to mesenchymal transition) and normalization of tumor vascularity. Treatment of triple negative breast cancer(TNBC) cell-lines with eribulin results in downregulation of mesenchymal markers with concomitant increase in expression of classical epithelial markers(Yoshida BJC 2014). In PDX models, eribulin improved blood perfusion in central region of tumors, increased vessel density, reduced vessel diameter, and reduced hypoxia. IBC is highly angiogenic, with increased microvessel density, higher fraction of proliferating endothelial cells and greater expression of pro-angiogenic genes compared with non-IBC(McCarthy CCR 2002). This preoperative study(EAC) exploits the angiogenic properties of IBC with the treatment scheme of eribulin(E) followed by doxorubicin/cyclosphosphamide(AC) in newly diagnosed HER2neg IBC.
Methods: Pts with HER2neg Stage III (cT4d,any N,M0) IBC are eligible if they have not received prior therapy for BC, have adequate organ function, cardiac ejection fraction > 50%, and willing to undergo 2 research biopsies (rbx) of the affected breast. Following baseline rbx, pts receive cycle 1, day(d)1 eribulin 1.4 mg/m2. A 2nd rbx occurs on d8, prior to dosing of E. Following 3 more cycles of E(1.4mg/m2 d1,d8,every 21d), pts receive 4 cycles of dose-dense AC(A-60 mg/m2,C-600mg/m2 every 14d). Pts with adequate disease response undergo mastectomy/axillary lymph node dissection followed by chest wall/regional lymph node radiation. Adjuvant endocrine therapy is used if hormone receptor positive. An imaging sub-study evaluates tumor perfusion via DCE-MRI pre and post 1st dose E.
Correlatives: To investigate whether E induces reversion of EMT in IBC, expression of 10 EMT-related genes are determined in each rbx, and normalization of tumor vessel phenotype are assessed by expression of 15 angiogenesis-related genes in rbx by RT-qPCR. Gene expression will be repeated on residual tumor at mastectomy. An imaging sub-study of DCE-MRI (10 pts) will assess vascular remodeling via changes in Ktrans , ve and vp determination of IBC region of interest, core and rim and changes in the iAUC computed pre and post 1st dose E.
Statistics: The primary endpoint is pCR. A Simon two-stage design is used. If the proportion of pts having pCR is < 0.10 then EAC is considered minimally effective, versus alternative hypothesis that EAC is worthy of further study if proportion pCR > 0.30. In the 1st stage, if < 2/16 pts have pCR, the study is stopped; if > 3 pts have pCR, the study proceeds. In the 2nd stage, EAC is rejected if < 4 of 25 pts have a pCR(α=0.10;β=0.10). Up to 25 pts will be enrolled. Secondary endpoints are residual cancer burden, disease-free survival, time to treatment failure and overall survival. Clinical trial information: NCT02623972.
Citation Format: Overmoyer B, Goel S, Regan M, Hirshfield-Bartek J, Schlosnagel E, Yeh E, Qin L, Bellon J, Nakhlis F, Jacene H, Winer E. A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT1-01-07.
Collapse
Affiliation(s)
- B Overmoyer
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - S Goel
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - M Regan
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - J Hirshfield-Bartek
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - E Schlosnagel
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - E Yeh
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - L Qin
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - J Bellon
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - F Nakhlis
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - H Jacene
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - E Winer
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA
| |
Collapse
|
3
|
Braunstein LZ, Taghian AG, Niemierko A, Salama L, Capuco A, Wong JS, Punglia RS, Bellon JR, MacDonald SM, Harris JR. Abstract P4-12-04: Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-12-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose/Objectives: Advances in breast-conserving therapy (BCT) have yielded local control rates comparable or superior to those of mastectomy. Here, we sought to identify risk factors associated with isolated local recurrence (LR) following BCT.
Materials/Methods: This study included a multi-institutional cohort of 2,233 consecutive breast cancer patients who underwent BCT between 1998 and 2007. Patient characteristics and disease parameters were stratified by age, subtype and nodal status. Biologic subtype was approximated by receptor status and tumor grade. No patients received HER2/neu-directed therapy. The association of clinicopathologic features with LR was evaluated using Cox proportional hazards regression models.
Results: At a median follow-up of 106 months, 69 LR events (3.1%) were observed. Among the overall cohort, 10-year freedom from LR was 95.9%. On univariate Cox regression analysis, risk factors associated with LR included subtype other than luminal A (hazard ratio [HR] for luminal B = 3.01, HER2 = 6.29, triple negative [TNBC] = 4.72; p<0.001 for each), younger age (HR of oldest versus youngest quartile = 0.43; p=0.005), regional lymph node involvement (HR for 4-9 involved nodes = 3.04; >9 nodes = 5.82; p<0.01 for each), positive resection margins (HR = 2.43; p=0.005), and high-grade disease (HR = 5.37; p <0.001). Presence of LVI (HR = 1.56; p=0.06) or 1-3 involved nodes (HR = 1.55; p=0.07) approached significance. Multivariate Cox regression demonstrated an association with LR among those with non-luminal A subtypes (HR for luminal B = 2.64, HER2 = 5.42, TNBC = 4.32; p<0.001 for each), younger age (HR for age >50 = 0.56; p=0.01), and any nodal disease (HR=1.06 per involved node; p<0.004).
Conclusions: BCT yields favorable outcomes for the large majority of patients, although increased LR was observed among those with non-luminal A subtypes, younger age, and increasing lymph node involvement. Risk factors for LR following BCT appear to be converging with those following mastectomy in the current era.
Citation Format: Braunstein LZ, Taghian AG, Niemierko A, Salama L, Capuco A, Wong JS, Punglia RS, Bellon JR, MacDonald SM, Harris JR. Breast cancer subtype, age and lymph node status as predictors of local recurrence following breast-conserving therapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-12-04.
Collapse
Affiliation(s)
- LZ Braunstein
- Harvard Radiation Oncology Program; Dana Farber Cancer Institute; Massachusetts General Hospital
| | - AG Taghian
- Harvard Radiation Oncology Program; Dana Farber Cancer Institute; Massachusetts General Hospital
| | - A Niemierko
- Harvard Radiation Oncology Program; Dana Farber Cancer Institute; Massachusetts General Hospital
| | - L Salama
- Harvard Radiation Oncology Program; Dana Farber Cancer Institute; Massachusetts General Hospital
| | - A Capuco
- Harvard Radiation Oncology Program; Dana Farber Cancer Institute; Massachusetts General Hospital
| | - JS Wong
- Harvard Radiation Oncology Program; Dana Farber Cancer Institute; Massachusetts General Hospital
| | - RS Punglia
- Harvard Radiation Oncology Program; Dana Farber Cancer Institute; Massachusetts General Hospital
| | - JR Bellon
- Harvard Radiation Oncology Program; Dana Farber Cancer Institute; Massachusetts General Hospital
| | - SM MacDonald
- Harvard Radiation Oncology Program; Dana Farber Cancer Institute; Massachusetts General Hospital
| | - JR Harris
- Harvard Radiation Oncology Program; Dana Farber Cancer Institute; Massachusetts General Hospital
| |
Collapse
|
4
|
Jacene HA, Overmoyer B, Schlosnagle EJ, Abbott A, Yeh E, Paolino J, Goel S, Culhane A, Bellon JR, Nakhlis F, Hirshfield-Bartek J, Van den Abbeele A. Abstract OT2-02-03: Pilot study of zirconium-89 bevacizumab positron emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot2-02-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inflammatory breast cancer (IBC) continues to have a poor prognosis despite standard tri-modality treatment with chemotherapy, mastectomy and radiation. Current methods of assessing primary tumor response (i.e., clinical exam and breast magnetic resonance imaging [MRI]) are limited for distinguishing residual tumor from responsive disease because of persistent morphologic changes in the breast. Therefore, the inability to accurately assess tumor response during treatment often results in the continuation of ineffective systemic chemotherapy until definitive pathologic evaluation at mastectomy. IBC has a highly angiogenic phenotype which is believed to play a role in this tumor's aggressiveness. The novel radiotracer Zirconium-89 (89Zr)-bevacizumab was developed for imaging tumor angiogenesis with PET. We hypothesize that, as an imaging biomarker of angiogenesis, 89Zr-bevacizumab-PET/CT is a more specific noninvasive functional imaging modality for detecting the presence of tumor angiogenesis compared to current diagnostic methods and will serve as a predictor of response to therapy in patients (pts) with IBC.
Methods: Pts with newly diagnosed HER2neg IBC who will receive preoperative chemotherapy are eligible for this pilot study. 89Zr-bevacizumab-PET/CT, breast MRI and FDG-PET/CT are performed before, after 2 cycles, and at the completion of preoperative therapy. Biopsies of primary IBC tumors are obtained prior to and after 2 cycles of preoperative therapy. At the completion of preoperative therapy, pts proceed to mastectomy or biopsy if ineligible to proceed to mastectomy based on current standards for assessing primary tumor response, i.e., clinical exam, breast MRI and lack of systemic progression. At the time of mastectomy, standard evaluation of the surgical specimen will determine pathologic response of IBC to preoperative chemotherapy. A research sample will be collected if residual cancer is present at the time of mastectomy for histologic evaluation of tumor angiogenesis.
Objectives/Correlatives: The primary objective is to determine feasibility of 89Zr-bevacizumab-PET/CT imaging in pts with IBC. The primary endpoint is assessment of radiolabeling of chelated bevacizumab and number of successfully acquired 89Zr-bevacizumab-PET/CT scans. Correlative studies will be performed on IBC tissue to assess extent of angiogenesis including microvessel density, vessel diameter, vascular pericyte coverage and tumor VEGF levels. Secondary objectives are: 1) To determine if 89Zr-bevacizumab accumulation in primary IBC tumors correlates with the extent of angiogenesis determined by correlative analysis on IBC tissue; 2) To assess the predictive value of 89Zr-bevacizumab-PET/CT after 2 cycles and at the end of preoperative therapy for determining pathologic response at mastectomy as given by residual cancer burden.
Statistics: This is an accrual, not statistical based, feasibility justification. Planned sample size is 10 in order to make a preliminary statement about feasibility and ability for 89Zr-bevacizumab-PET/CT to serve as a surrogate in vivo biomarker of tumor angiogenesis and response to preoperative chemotherapy.
Clinical Trial Information: NCT01894451.
Citation Format: Jacene HA, Overmoyer B, Schlosnagle EJ, Abbott A, Yeh E, Paolino J, Goel S, Culhane A, Bellon JR, Nakhlis F, Hirshfield-Bartek J, Van den Abbeele A. Pilot study of zirconium-89 bevacizumab positron emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT2-02-03.
Collapse
Affiliation(s)
- HA Jacene
- Dana-Farber Cancer Institute; Brigham and Women's Hospital; Co-First Authors Contributing Equally to This Work
| | - B Overmoyer
- Dana-Farber Cancer Institute; Brigham and Women's Hospital; Co-First Authors Contributing Equally to This Work
| | - EJ Schlosnagle
- Dana-Farber Cancer Institute; Brigham and Women's Hospital; Co-First Authors Contributing Equally to This Work
| | - A Abbott
- Dana-Farber Cancer Institute; Brigham and Women's Hospital; Co-First Authors Contributing Equally to This Work
| | - E Yeh
- Dana-Farber Cancer Institute; Brigham and Women's Hospital; Co-First Authors Contributing Equally to This Work
| | - J Paolino
- Dana-Farber Cancer Institute; Brigham and Women's Hospital; Co-First Authors Contributing Equally to This Work
| | - S Goel
- Dana-Farber Cancer Institute; Brigham and Women's Hospital; Co-First Authors Contributing Equally to This Work
| | - A Culhane
- Dana-Farber Cancer Institute; Brigham and Women's Hospital; Co-First Authors Contributing Equally to This Work
| | - JR Bellon
- Dana-Farber Cancer Institute; Brigham and Women's Hospital; Co-First Authors Contributing Equally to This Work
| | - F Nakhlis
- Dana-Farber Cancer Institute; Brigham and Women's Hospital; Co-First Authors Contributing Equally to This Work
| | - J Hirshfield-Bartek
- Dana-Farber Cancer Institute; Brigham and Women's Hospital; Co-First Authors Contributing Equally to This Work
| | - A Van den Abbeele
- Dana-Farber Cancer Institute; Brigham and Women's Hospital; Co-First Authors Contributing Equally to This Work
| |
Collapse
|
5
|
Warren LE, Chen YH, Halasz LM, Capuco A, Bellon JR, Brock JE, Punglia RS, Wong JS, Harris JR. Abstract P3-17-07: Improved long-term outcomes of breast-conserving therapy for women with ductal carcinoma in situ. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p3-17-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Improved mammographic and surgical techniques and pathologic evaluation, particularly greater attention to achieving negative margins, have resulted in decreased local recurrence rates for patients with ductal carcinoma in situ (DCIS). This is an updated analysis of local outcomes after breast-conserving surgery (BCS) and adjuvant radiation therapy (RT) at a single institution in the modern era.
Methods and Materials: We retrospectively reviewed the records of 245 women treated for DCIS with BCS and RT between 2001 and 2007. Competing risk analysis was used to calculate local recurrence (LR) as a first event with the development of a second non-breast malignancy, contralateral breast cancer, and death as competing first events. The median age at diagnosis was 54 (range, 32-84) and 174 (93%) women had estrogen receptor (ER) and/or progesterone receptor (PR) positive disease. Ninety-five (39%) were grade III. Specimen radiograph during surgery was obtained for 223 women (91%) and post-operative mammogram for 102 (42%). Half underwent more than one excision. The institutional goal for margins during the study period was 3 mm or greater; final margins were >2 mm in 221 (90%). All received adjuvant radiation therapy to the whole breast (median whole breast dose: 4400; range, 4000 - 5220) and nearly all (99%) received a boost to the surgical cavity (median boost dose: 1600; range, 800 – 1800). Among patients with ER and/or PR+ disease, 105 (60%) received adjuvant hormonal therapy.
Results: At a median follow-up of 10.6 years, 4 patients had a LR (2 DCIS, 2 invasive ductal carcinoma) as a first event with a cumulative LR incidence of 0.0% and 1.5% at 5 and 10 years, respectively. The 5 and 10-year cumulative incidence of the competing first events is seen in the table below. Twenty women developed a contralateral breast cancer (CBC; 8 DCIS, 12 invasive carcinoma), 13 were diagnosed with a second non-breast malignancy (3 endometrial, 2 fallopian tube, 1 gallbladder, 1 leukemia and thyroid, 4 lung, 1 ovarian, and 1 uterine), and 7 died. Family history, age at diagnosis, and receipt of hormonal therapy were not significantly associated with the development of CBC on univariable analysis (all p>0.05).
Incidence of local recurrence and competing eventsEvent5-year cumulative incidence10-year cumulative incidenceLocal recurrence0.0%1.5%Contralateral Breast Cancer2.5%7.9%Second non-breast malignancy2.6%4.5%Death1.2%3.5%
Conclusions: With longer follow-up, our rates of local recurrence following breast-conserving therapy for DCIS remain very low (1.5% at 10 years). The vast majority of patients had >2 mm margins, specimen radiographs, and received a tumor bed boost. The majority (60%) of patients with hormone receptor positive disease received adjuvant endocrine therapy. The 10-year incidence of CBC was higher than expected. Predisposing factors for the development of CBC are worthy of investigation.
Citation Format: Warren LE, Chen Y-H, Halasz LM, Capuco A, Bellon JR, Brock JE, Punglia RS, Wong JS, Harris JR. Improved long-term outcomes of breast-conserving therapy for women with ductal carcinoma in situ [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-17-07.
Collapse
Affiliation(s)
- LE Warren
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of Washington, Seattle, WA; Brigham and Women's Hospital, Boston, MA
| | - Y-H Chen
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of Washington, Seattle, WA; Brigham and Women's Hospital, Boston, MA
| | - LM Halasz
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of Washington, Seattle, WA; Brigham and Women's Hospital, Boston, MA
| | - A Capuco
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of Washington, Seattle, WA; Brigham and Women's Hospital, Boston, MA
| | - JR Bellon
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of Washington, Seattle, WA; Brigham and Women's Hospital, Boston, MA
| | - JE Brock
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of Washington, Seattle, WA; Brigham and Women's Hospital, Boston, MA
| | - RS Punglia
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of Washington, Seattle, WA; Brigham and Women's Hospital, Boston, MA
| | - JS Wong
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of Washington, Seattle, WA; Brigham and Women's Hospital, Boston, MA
| | - JR Harris
- Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of Washington, Seattle, WA; Brigham and Women's Hospital, Boston, MA
| |
Collapse
|
6
|
Hazra A, Warren L, Nakhlis F, Bellon JR, Hirshfield-Bartek J, Jacene H, Yeh ED, Dominici L, Schlosnagle E, Hirko K, Overmoyer B. Abstract P6-18-03: Tumor profiling of inflammatory breast cancer: Advancing the tools needed for precision medicine. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-18-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Inflammatory breast cancer (IBC) is a rare and highly lethal form of breast cancer, accounting for approximately 10% of breast cancer mortality in the US. The clinical presentation of IBC includes rapid onset of symptoms, erythema > 1/3 of the breast, and edema. The genomic changes underlying the clincopathologic manifestations of IBC are yet unknown. Identification of a unique molecular signature in de novo IBC may provide insight into the biology of this disease, allowing further investigation into the etiology and treatment of this aggressive disease. In previous studies, supervised analysis of gene expression data from surgical tissue specimens identified a molecular-subtype independent 79-gene signature associated with IBC compared to locally-advanced non-IBC. In this study, we propose to identify a gene expression signature associated with IBC using breast specimens collected from patients with non-metastatic IBC prior to initiating preoperative systemic treatment.
Methods: Formalin fixed paraffin embedded (FFPE) core biopsy specimens were collected from patients with inflammatory breast cancer prior to initiating systemic therapy. All specimens underwent centralized pathology review at Brigham and Women's Hospital, and the clinical diagnosis was confirmed through evaluation by the Dana Farber Cancer Institute Inflammatory Breast Cancer Program. Sufficient RNA and DNA were simultaneously extracted from 14 biopsy specimens using the Qiagen AllPrep Kit. The RNA was amplified using the Sensation kit and profiled using the Affymetrix Human Transcriptome Array (HTA) 2.0. DNA was profiled for druggable somatic mutations and genome-wide copy number variations using the Affymetrix OncoScan Array.
Results: Pearson correlation coefficients for overall gene expression for 4 technical replicates included in the HTA ranged from r=0.993 - 0.994 and suggest excellent reproducibility in archival biopsy tissue. In preliminary analyses, 765 mRNA transcripts and 335 non-coding transcripts were differentially expressed based on clinical presentation features. The strongest differential association for rapid onset of disease was observed for alternately spliced variants in the TSPAN1 gene. Somatic mutations in PIK3CA were detected in 3 of the IBC patients. Additional paired assays as well as single-gene and pathway analyses, and integrated analyses of the genome and transcriptome using the R/Bioconductor packages are ongoing.
Conclusion: An understanding of the genomic changes that contribute to the unique presentation and biologic features associated with IBC should lead to a significant impact on identifying etiologic risk factors and in optimizing treatment strategies. Our findings to date suggest a robust and reproducible method for genomic investigation using standard diagnostic breast core biopsies among IBC patients, and may inform profiling of biopsy specimens for other cancer types. The completion of this study will provide biological insights into the molecular mechanisms driving IBC and may identify clinically actionable targets for novel IBC therapies that warrant further exploration.
Citation Format: Hazra A, Warren L, Nakhlis F, Bellon JR, Hirshfield-Bartek J, Jacene H, Yeh ED, Dominici L, Schlosnagle E, Hirko K, Overmoyer B. Tumor profiling of inflammatory breast cancer: Advancing the tools needed for precision medicine. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-18-03.
Collapse
Affiliation(s)
- A Hazra
- Brigham and Women's Hospital, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Dana Farber Cancer Institute, Boston, MA
| | - L Warren
- Brigham and Women's Hospital, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Dana Farber Cancer Institute, Boston, MA
| | - F Nakhlis
- Brigham and Women's Hospital, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Dana Farber Cancer Institute, Boston, MA
| | - JR Bellon
- Brigham and Women's Hospital, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Dana Farber Cancer Institute, Boston, MA
| | - J Hirshfield-Bartek
- Brigham and Women's Hospital, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Dana Farber Cancer Institute, Boston, MA
| | - H Jacene
- Brigham and Women's Hospital, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Dana Farber Cancer Institute, Boston, MA
| | - ED Yeh
- Brigham and Women's Hospital, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Dana Farber Cancer Institute, Boston, MA
| | - L Dominici
- Brigham and Women's Hospital, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Dana Farber Cancer Institute, Boston, MA
| | - E Schlosnagle
- Brigham and Women's Hospital, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Dana Farber Cancer Institute, Boston, MA
| | - K Hirko
- Brigham and Women's Hospital, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Dana Farber Cancer Institute, Boston, MA
| | - B Overmoyer
- Brigham and Women's Hospital, Boston, MA; Harvard T.H. Chan School of Public Health, Boston, MA; Dana Farber Cancer Institute, Boston, MA
| |
Collapse
|
7
|
Cifter G, Chin J, Cifter F, Sinha N, Bellon J, Sajo E, Ngwa W. WE-G-BRE-09: Targeted Radiotherapy Enhancement During Accelerated Partial Breast Irradiation (ABPI) Using Controlled Release of Gold Nanoparticles (GNPs). Med Phys 2014. [DOI: 10.1118/1.4889484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
8
|
Nakhlis F, Regan MM, Warren LE, Bellon JR, Yeh ED, Jacene HA, Golshan M, Duggan MM, Dominici LS, Hirshfield-Bartek J, Mullaney EE, Overmoyer BA. Abstract P6-12-05: The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p6-12-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction. Inflammatory breast cancer (IBC) is a rare and aggressive subtype of breast cancer treated with multimodality therapy consisting of preoperative systemic therapy (PST) followed by modified radical mastectomy (MRM) and chest wall and regional nodal radiation and if appropriate extended biologic therapy and/or endocrine therapy. In non-IBC patients (pts) the degree of pathologic response to PST has been shown to correlate with time to recurrence (TTR) and overall survival (OS). We sought to determine if the degree of pathologic response predicts clinical outcomes in IBC pts.
Methods. With IRB approval, we reviewed the records of IBC pts seen at Dana Farber/Brigham and Women's Cancer Center between 1997 and 2012. From 117 IBC pts, all of whom have had PST, followed by MRM and radiotherapy, 98 pts with stage III disease were analyzed. Statistical analysis: TTR - time from surgery until first locoregional or distant recurrence, or censored at date of last follow-up or death of other causes. OS - time from surgery until death from any cause or censored at date the pt last known to be alive. Pathologic complete response (pCR) - no residual invasive disease in the breast and axillary lymph nodes. Pathologic response to PST, disease characteristics (estrogen (ER), progesterone receptor (PR), Her2 status, grade, histology) and receipt of Her2-directed PST when indicated were evaluated as predictors of TTR and OS by Cox model.
Results 42 (43%) of 98 pts have experienced recurrence (1 local, 4 locoregional+distant, 31 distant). Median TTR = 5.1yrs. 40 pts died; 4 of other causes; median OS = 5.1yrs. pCR was associated with improved TTR (HR = 0.22, 95% CI 0.07-0.70, p = 0.011 univariate analysis); 5yr freedom from recurrence was 81% vs 40% with vs without pCR. The association remained after adjusting for disease and treatment characteristics (HR = 0.25, 95% CI 0.07-0.85, p = 0.026 multivariable). pCR was associated with better OS (HR = 0.35, 0.12-1.03, p = 0.06 multivariable).
TTR and OS according to pCR or no pCRFreedom from recurrenceno pCRpCRAll2-yr58%88%64%2-yr47%81%55%5-yr40%81%51%Median TTR2.8 yrsnot reached5.1 yrsOSno pCRpCRAll2-yr81%100%85%3-yr62%87%67%5-yr44%72%50%Median OS3.9 yrsnot reached5.1 yrs
In multivariable modeling of TTR, lower tumor grade was associated with better outcome. Pts with ER, PR and Her2 negative or HER2+ disease without preoperative trastuzumab (H) had worse outcome (median TTR 0.9yr and 1.4yr); those with ER+ and/or PR+ HER2- disease and those with HER2+ disease who received preoperative H had 5yr freedom from recurrence 74% and 82%.
TTR and OS according to ER, PR and Her2 status and receipt of neoadjuvant trastuzumab (H)Freedom from recurrenceER/PR/Her2-ER/PR+, HER2-ER/PR+, HER2+ no HER/PR+, HER2+ yes H2-yr25%80%38%92%3-yr25%74%0%82%5-yr15%74%0%82%Median TTR0.9 yrs11 yrs1.4 yrsnot reached
Conclusions. Hormone receptor and HER2 status are independent prognostic features in IBC, similar to those seen in non-IBC. In addition, anti-Her2-directed preoperative therapy is important to improve outcomes of IBC pts with HER2+ disease. Understanding these features should help in the development of optimal therapies for IBC.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-12-05.
Collapse
Affiliation(s)
- F Nakhlis
- Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - MM Regan
- Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - LE Warren
- Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - JR Bellon
- Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - ED Yeh
- Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - HA Jacene
- Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - M Golshan
- Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - MM Duggan
- Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - LS Dominici
- Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | | | - EE Mullaney
- Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| | - BA Overmoyer
- Dana Farber/Brigham and Women's Cancer Center, Boston, MA
| |
Collapse
|
9
|
Warren LE, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR. Abstract P3-10-06: Patterns of failure in patients with inflammatory breast cancer: the case for aggressive local/regional treatment. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-10-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: While the survival of patients with inflammatory breast cancer (IBC) is dictated by the status of their distant metastases, local/regional control remains an important component of quality of life. We have sought to determine patterns of local/regional recurrence (LRR) in patients presenting with inflammatory breast cancer.
Methods: The medical records of 92 patients (pts) diagnosed with IBC from 1997 until 2007 were reviewed. Pt cohorts were stratified by disease burden at presentation (metastatic or local/regional) and their tumor, treatment, and disease course were analyzed. Primary outcomes were time from diagnosis to LRR, time to distant recurrence, and overall survival (OS). Median follow-up (MFU) for the entire cohort was 6 years (yrs) (range 0.1 to 12.7 yrs); for those patients who presented with metastatic disease versus only local/regional disease, MFU is 2 yrs and 6 yrs, respectively. This study was approved by the hospital institutional review board.
Results: Median age at diagnosis was 49 yrs (range 24 to 72). 68 (74%) patients were without evidence of metastatic disease on presentation. With 6yr MFU, 40/68 (59%) had disease recurrence at either local or distant sites, and 15/68 (22%) had documented LRR, either as the first or subsequent site of recurrence. Estimated 5yr OS is 64%.
24 (26%) pts presented with metastatic disease (lung, liver, distant lymph nodes, pleura). All of the 24 pts presenting with metastatic disease developed systemic disease progression; 12/24 (50%) also developed LRR, and for 9/12 pts the LRR was first progression or concurrent with distant progression. Eleven of the 24 pts did not receive radiation or surgery; and within this cohort, 7 (64%) pts developed LLR at a median time of 9 months after diagnosis. Six pts received radiation therapy without surgery; 3/6 (50%) developed LRR. One pt had surgery alone; this patient was not known to have LRR, although had limited follow-up. Six pts received radiation therapy and surgery; 1 for palliation and 5 to prevent LRR. Of these 5 pts, 1/5 (20%) developed LRR that extended to the contralateral breast at 1.2y after diagnosis. Among the 24 patients, the cumulative incidence of LRR was 29%, 37%, and 43% at 1yr, 2yr, and 3yr (accounting for competing risk of death). The median OS was 2.9 yrs and estimated 5yr OS was 36%.
Conclusions: Pts with inflammatory breast carcinoma presenting with metastatic disease are at high risk for local/regional disease progression. Aggressive local therapy should be considered to prevent symptoms of uncontrolled local disease, despite an uncertain impact upon OS.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-10-06.
Collapse
Affiliation(s)
- LE Warren
- Harvard Medical School, Boston, MA; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - MM Regan
- Harvard Medical School, Boston, MA; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - F Nakhlis
- Harvard Medical School, Boston, MA; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - ED Yeh
- Harvard Medical School, Boston, MA; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - HA Jacene
- Harvard Medical School, Boston, MA; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - J Hirshfield-Bartek
- Harvard Medical School, Boston, MA; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - BA Overmoyer
- Harvard Medical School, Boston, MA; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - JR Bellon
- Harvard Medical School, Boston, MA; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
| |
Collapse
|
10
|
Ng SK, Lyatskaya Y, Hesser J, Jeung A, Mostafavi H, Bellon J, Wong J, Zygmanski P. SU-E-J-57: Clinical Protocol for DTS-Based APBI Setup: Optimal Data Acquisition, Reconstruction and Registration Parameters Using Varian DTS Software. Med Phys 2011. [DOI: 10.1118/1.3611825] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
11
|
Lyatskaya Y, Cormack R, Bellon J. SU-E-T-333: Validation of Align RT System for Breast Radiation Therapy with Deep Inspiration Breath Hold (DIBH) Technique. Med Phys 2011. [DOI: 10.1118/1.3612287] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
12
|
Ng SK, Zygmanski P, Buehler A, Stsepankou D, Hesser J, Bellon J, Lyatskaya Y. SU-GG-J-20: Methods for Improvement of Clip Localization in CBTS for Breast Cancer Patients Setup Verification. Med Phys 2010. [DOI: 10.1118/1.3468244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
13
|
Moreno-Peral P, Bellon J, Motrico E, Moreno-Küstner B, Oliván-Blazquez B, Fernández A, Fernández C, Rüntel A, Rodriguez A, Ballesta M, Payo J, Amezcua M. P02-287 - Primary prevention in depression. How to inform primary care attendees about their risk level and risk profile of major depression? Eur Psychiatry 2010. [DOI: 10.1016/s0924-9338(10)70913-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
14
|
Bhagwat M, Blessing M, Lyatskaya Y, Bellon J, Zygmanski P. SU-FF-I-119: KV Beam Model for OBI and Extraction of Water Equivalent Depths for Primary and Scatter Contributions. Med Phys 2009. [DOI: 10.1118/1.3181240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
15
|
Affiliation(s)
- D. Cozzolino
- The Australian Wine Research Institute, PO Box 197, Glen Osmond, SA 5064, Australia
- The Cooperative Research Centre for Viticulture, PO Box 154, Glen Osmond, SA 5064, Australia
| | - L. Flood
- The Australian Wine Research Institute, PO Box 197, Glen Osmond, SA 5064, Australia
| | - J. Bellon
- The Australian Wine Research Institute, PO Box 197, Glen Osmond, SA 5064, Australia
| | - M. Gishen
- The Australian Wine Research Institute, PO Box 197, Glen Osmond, SA 5064, Australia
| | - M. De Barros Lopes
- The Australian Wine Research Institute, PO Box 197, Glen Osmond, SA 5064, Australia
| |
Collapse
|
16
|
Cozzolino D, Flood L, Bellon J, Gishen M, De Barros Lopes M. Combining near infrared spectroscopy and multivariate analysis as a tool to differentiate different strains ofSaccharomyces cerevisiae: a metabolomic study. Yeast 2006; 23:1089-96. [PMID: 17083133 DOI: 10.1002/yea.1418] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Near-infrared (NIR) spectroscopy has gained wide acceptance within the food and agriculture industries as a rapid analytical tool. NIR spectroscopy offers the advantage of rapid, non-destructive analysis and routine operation is simple and opens the possibility of using spectra to obtain the 'fingerprint' of a sample. The aim of this study was to explore the potential of combining visible (VIS) and near-infrared (NIR) spectroscopy, together with multivariate analysis, in establishing the function of genes, by investigating the metabolic profiles produced by Saccharomyces cerevisiae deletion strains sourced from the EUROSCARF yeast collection. Spectra (400-2500 nm) were acquired with a FOSS NIRSystems6500 (Foss NIRSystems), in transmittance mode. Principal component analysis (PCA) and linear discriminant analysis (LDA) were used in order to visualize graphically the relative differences and similarities of yeast deletion strains. VIS and NIR spectroscopy showed great promise as a screening tool for both discriminating between yeast strains and grouping strains with deletions in genes that disturb similar metabolic pathways. These results indicate that the methods may be useful in defining the function of genes that produce no obvious phenotype.
Collapse
Affiliation(s)
- D Cozzolino
- The Australian Wine Research Institute, Glen Osmond, SA, Australia.
| | | | | | | | | |
Collapse
|
17
|
|
18
|
Harris L, Burstein H, Gelman R, Freidman P, Kuter I, Borges V, Kaelin C, Bellon J, Smith D, Winer E. 397 Preoperative trastuzumab and vinorelbine (HN) is a well-tolerated, active regimen for Her2 3+/FISH+stage II/III breast cancer. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90429-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
19
|
Schwartz DL, Einck J, Bellon J, Laramore GE. Fast neutron radiotherapy for soft tissue and cartilaginous sarcomas at high risk for local recurrence. Int J Radiat Oncol Biol Phys 2001; 50:449-56. [PMID: 11380233 DOI: 10.1016/s0360-3016(00)01586-8] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
PURPOSE The practice policy at the University of Washington has been to employ fast neutron radiotherapy for soft tissue sarcoma lesions with prognostic features predictive for poor local control. These include gross residual disease/inoperable disease, recurrent disease, and contaminated surgical margins. Cartilaginous sarcomas have also been included in this high-risk group. This report updates and expands our previously described experience with this approach. METHODS AND MATERIALS Eighty-nine soft tissue sarcoma lesions in 72 patients were treated with neutron radiotherapy in our department between 1984 and 1996. Six patients, each with solitary lesions, were excluded from analysis due to lack of follow-up. Seventy-three percent were treated with fast neutron radiation alone, the rest with a combination of neutrons and photons. Median neutron dose was 18.3 nGy (range 4.8-22). Forty-two patients with solitary lesions were treated with curative intent. Thirty-one patients (including 7 previously treated with neutrons) with 41 lesions were treated with the goal of local palliation. Tumors were predominantly located in the extremity and torso. Thirty of 35 (85%) of curative group patients treated postoperatively had close or positive surgical margins. Thirty-four (82%) lesions treated for palliation were unresectable. Thirty-five patients (53%) were treated at the time of recurrence. Median tumor size at initial presentation was 8.0 cm (range 0.6-29), median treated gross disease size was 5.0 cm (range 1-22), and 46/69 evaluable lesions (67%) were judged to be of intermediate to high histologic grade. Fourteen patients (21%) had chondrosarcomas. RESULTS Median follow-up was 6 months (range 2-47) and 38 months (range 2-175) for the palliative and curative groups, respectively. Kaplan-Meier estimates were obtained for probability of local relapse-free survival (68%), distant disease-free survival (59%), cause-specific survival (68%), and overall survival (66%) at 4 years for the curatively treated group. For the palliatively treated group, estimated local relapse-free survival at 1 year was 62%. Log-rank analysis of the curative group revealed recurrent disease to be the only risk factor predictive for significantly worse local and distant disease-free survival. Intermediate-/high-grade histology was predictive for inferior overall survival. Effective clinical response was documented for 21/27 (78%) lesions treated palliatively. Ten patients (15%) experienced serious chronic radiation-related complications. All of these patients had clinical situations requiring delivery of high neutron doses and/or large radiotherapy fields. CONCLUSION Fast neutron radiotherapy is locally effective for soft tissue and cartilaginous sarcomas having well-recognized high-risk features. Results in the palliative setting appear to be particularly encouraging, with neutrons frequently providing significant symptomatic response for gross disease, with minimal serious chronic sequelae. Fast neutron radiotherapy should be considered in patients at high risk for local recurrence in both the curative and palliative settings.
Collapse
Affiliation(s)
- D L Schwartz
- Department of Radiation Oncology, Seattle VA Medical Center/Puget Sound Health Care System, WA 98108, USA.
| | | | | | | |
Collapse
|
20
|
Abstract
Positron emission tomography (PET) has become an important diagnostic tool in oncology. We briefly review the physics of PET, instrumentation for imaging, and approaches to radiopharmaceutical production. The principles underlying the use of [(18)F]-fluorodeoxyglucose (FDG) are described, and the clinical experience with FDG pertinent to radiation oncology is reviewed. Finally, preliminary studies using PET tracers with greater specificity than FDG for tumor imaging are discussed. Emphasis is placed on underlying principles and those aspects of oncologic PET most applicable to radiation oncology.
Collapse
Affiliation(s)
- D A Mankoff
- Division of Nuclear Medicine, University of Washington, Seattle, WA, USA.
| | | |
Collapse
|
21
|
Bellon JR, Lindsley KL, Ellis GK, Gralow JR, Livingston RB, Austin Seymour MM. Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer. Int J Radiat Oncol Biol Phys 2000; 48:393-7. [PMID: 10974452 DOI: 10.1016/s0360-3016(00)00636-2] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE Evidence supports the inclusion of the taxanes in the treatment of breast cancer. A recent randomized trial has shown a survival advantage to the addition of paclitaxel in the adjuvant treatment of node-positive patients. Several studies have suggested diminished local control if adjuvant radiation is delayed, while in vitro and in vivo studies have demonstrated a benefit of concurrent administration of taxanes with radiation. For these reasons, we began in 1995 to administer radiation therapy concurrently with the taxanes in advanced breast cancer. This retrospective review examines the feasibility of such treatment. METHODS AND MATERIALS Forty-four patients were treated with concurrent radiation and either paclitaxel (29 patients) or docetaxel (15 patients). One patient received both paclitaxel and docetaxel. Eighteen patients were treated for recurrent disease, 9 had received prior radiation. Toxicity was assessed by the RTOG scale for acute and late effects. RESULTS Concurrent radiation and taxane chemotherapy was well tolerated. Nine patients (20%) experienced Grade 3 acute skin toxicity. This was more likely with docetaxel than paclitaxel (p = 0. 04). Among patients undergoing breast conservation, there were no Grade 3 toxicities. With a median follow-up of 11 months, 1 patient has developed breast fibrosis. CONCLUSION Concurrent administration of both paclitaxel and docetaxel with radiation resulted in acceptable toxicity. Overall, the acute skin toxicity seen with docetaxel was more pronounced. However, among patients undergoing breast conservation the taxanes were both well tolerated. Further study is necessary to assess the impact of concurrent treatment on long-term outcome.
Collapse
Affiliation(s)
- J R Bellon
- Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA, USA
| | | | | | | | | | | |
Collapse
|
22
|
Bellon J, Wallner K, Ellis W, Russell K, Cavanagh W, Blasko J. Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999; 43:579-81. [PMID: 10078640 DOI: 10.1016/s0360-3016(98)00466-0] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
PURPOSE To determine the necessity of preoperative evaluation of pubic arch interference in patients with small prostate volumes. METHODS AND MATERIALS CT scans from 97 consecutive, unselected patients with stage T1 or T2 prostatic carcinoma who had transperineal I-125 or Pd-103 implants at the University of Washington in 1997 were analyzed for pubic arch interference. Transrectal ultrasound (TRUS) was performed with 6.0-MHz transducer with the patient in the lithotomy position and the patient's thighs vertical, similar to that used during the implant procedure. CT scans were obtained with the patient in the supine position, with 0.5-cm images taken at every 0.5 cm. To check for potential arch interference, the largest prostate cross-section was overlaid on the narrowest portion of the pubic arch. The overlap of the pubic arch and the prostate margin is measured at right angles to the inner pubic surface. The prostate volume obtained from the TRUS images was compared with the degree of pubic arch interference in order to determine whether TRUS volume predicted for interference. RESULTS There was considerable variability in pubic arch interference between patients. The mm of pubic arch overlap with the prostatic margin varied from -11 mm to 20 mm. Patients with larger prostate volumes generally had more pubic arch interference, but the degree of interference was only loosely related to the prostate volume (r = 0.46). CONCLUSIONS The degree of pubic arch interference is highly variable from one patient to the next and the TRUS volume cannot reliably predict patients who do or do not need a pelvic CT to detect potential arch interference.
Collapse
Affiliation(s)
- J Bellon
- Department of Radiation Oncology, University of Washington, Seattle, USA
| | | | | | | | | | | |
Collapse
|
23
|
Bernard D, Verschraegen G, Claeys G, Bellon J, Vaneechoutte M. Diagnosis of intravascular device related sepsis by a continuous monitoring blood culture system. Intensive Care Med 1996; 22:829-30. [PMID: 8880254 DOI: 10.1007/bf01709528] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
24
|
Smith AS, Bellon JR. Parallel and spiral flow patterns of vertebral artery contributions to the basilar artery. AJNR Am J Neuroradiol 1995; 16:1587-91. [PMID: 7502960 PMCID: PMC8337771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
PURPOSE To demonstrate that the in vivo flow from individual vertebral arteries can be imaged and tracked in the basilar artery by use of saturation planes with three-dimensional time of flight MR angiography. METHODS Twenty volunteers were studied with intracranial three-dimensional time of flight angiography MR. The MR angiography was repeated with saturation of the individual vertebral arteries. Flow voids and signal intensity within the basilar and posterior cerebral arteries were evaluated for flow patterns. RESULTS Of 15 volunteers with a "normal" vertebrobasilar anatomy, 80% demonstrated a pattern of flow within the basilar artery in which the contributing vertebral components remained ipisilateral. This pattern was called "parallel." A "spiral" pattern of rotation of the contributing vertebral components was found in 20% of studies. The inflow to the posterior cerebral arteries could be identified from specific vertebral contributions and was related to the size-dominance of the vertebral artery. CONCLUSION There is nonadmixture of vertebral artery flows of variable duration within the basilar artery; at least two patterns of flow can be described within the basilar artery. The method presented is a simple technique for determining vertebral artery flow components with routine software and without secondary data manipulation.
Collapse
Affiliation(s)
- A S Smith
- Department of Radiology, University Hospitals of Cleveland (Ohio), Case Western Reserve University, USA
| | | |
Collapse
|
25
|
Affiliation(s)
- J R Bellon
- School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
| | | | | |
Collapse
|
26
|
Abstract
The distribution of beta-lactamases of indoor and outdoor origin was studied over a 9-month period. We consecutively selected 37 indoor and 48 outdoor strains of the following genera of the Enterobacteriaceae family: Escherichia (species coli), Enterobacter, Proteus, and Klebsiella. All isolates were resistant to amoxicillin and/or cephalothin and/or cefamandole. All strains showed beta-lactamase activity. We characterized the enzymes by an isoelectric focusing method and by a disc diffusion test. For both indoor and outdoor isolates we found that plasmid-mediated beta-lactamases were encountered mostly in the E. coli and Klebsiella species, whereas chromosomally mediated enzymes predominated in the Proteus and Enterobacter species. No significant difference in distribution of beta-lactamases could be found comparing both groups, but it was noted that chromosomally mediated beta-lactamases predominated in the Department of Urology, while plasmid-mediated beta-lactamases prevailed in other departments (p less than 0.05).
Collapse
Affiliation(s)
- J Bellon
- Department of Medical Microbiology, State University and University Hospital of Leiden, The Netherlands
| | | |
Collapse
|
27
|
Delanghe J, Bellon J, De Buyzere M, Van Daele G, Leroux-Roels G. Elimination of glucose interference in enzymatic determination of inulin. Clin Chem 1991; 37:2017-8. [PMID: 1934489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
28
|
Delanghe J, Bellon J, De Buyzere M, Van Daele G, Leroux-Roels G. Elimination of glucose interference in enzymatic determination of inulin. Clin Chem 1991. [DOI: 10.1093/clinchem/37.11.2017] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
29
|
Bellon J, Weise B, Verschraegen G, De Meyere M. Selective streptococcal agar versus blood agar for detection of group A beta-hemolytic streptococci in patients with acute pharyngitis. J Clin Microbiol 1991; 29:2084-5. [PMID: 1774341 PMCID: PMC270269 DOI: 10.1128/jcm.29.9.2084-2085.1991] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
In a study on acute pharyngitis in general practice, we compared a selective group A streptococcal agar (ssA) for the recovery of group A beta-hemolytic streptococci (GABHS) with sheep blood agar. All plates were incubated at 36 degrees C in an atmosphere reinforced with 5% CO2 for 48 h with a first reading after 24 h. A total of 197 GABHS isolates were obtained from 721 throat cultures on both media. The recovery of GABHS was significantly higher after 48 h of incubation for both media. With the ssA plate, we detected significantly more GABHS after 24 h as well as after 48 h of incubation. The ssA plate reduced normal flora qualitatively and quantitatively. In conclusion, ssA is more sensitive and specific for the detection of GABHS than sheep blood agar and moreover easier to read. We recommend incubation for 48 h.
Collapse
Affiliation(s)
- J Bellon
- Department of Bacteriology, University Hospital, Ghent, Belgium
| | | | | | | |
Collapse
|
30
|
Jaume-Roig B, Simon-Bouy B, Taillandier A, Serre JL, Antich J, Bellon J, Boué J, Boué A. Genotyping of the Spanish cystic fibrosis population at the delta F508 mutation site and RFLP linked loci. Hum Genet 1990; 85:410-1. [PMID: 1976593 DOI: 10.1007/bf02428284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Spanish families (n = 75) with at least one affected cystic fibrosis (CF) child were typed for restriction fragment length polymorphisms (RFLPs) by the probes XV2c, KM19, and pMP6d-9. These families were also studied at the 508 mutation site by the polymerase chain reaction method. We have studied the linkage disequilibrium between these markers and the CF mutations, the probable number of independent secondary CFX (non-delta F508) mutations, and the genetic differences between Spain and Western Europe.
Collapse
Affiliation(s)
- B Jaume-Roig
- Unité 73, Institut National de la Santé et de la Recherche Médicale, Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Holvoet K, De Vos M, Bellon J, Duyck MC, Bellon A. Identification of aminoglycoside-modifying enzymes in a medium-size hospital. Acta Clin Belg 1988; 43:261-6. [PMID: 2847466 DOI: 10.1080/17843286.1988.11717942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
32
|
Zapatero J, Bellon J, Baamonde C, Aragoneses FG, Cubillo J, Orusco E, Perez Gallardo M, Zapatero Domínguez J, Folqué E. Primary choriocarcinoma of the lung. Presentation of a case and review of the literature. Scand J Thorac Cardiovasc Surg 1982; 16:279-81. [PMID: 6763331 DOI: 10.3109/14017438209101063] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
A 67-year-old man with persistent haemoptysis was found to have primary choriocarcinoma of the lung. Only previous cases were found in the international literature. Hyperprolanuria B would seem to be the most important factor for early diagnosis. The recommended treatment is surgery in accordance with the oncologic criteria for bronchopulmonary cancer.
Collapse
|